SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F)

Potiron, Vincent; Drabkin, HA; Roche, J. F.

doi:10.4267/2042/44387

Cited by 2 publications

(2 citation statements)

References 20 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second semaphorin gene mapped in 3p21.3, SEMA3F (previously SEMAIV, [6, 96] has been studied for its in vivo tumor suppressor function. The first evidence came from transfection of a mouse tumor cell line by a 80 Kb genomic clone containing SEMA3F (and additional sequences) that suppressed tumor growth [97].…”

Section: Semaphorins In Lung Cancermentioning

confidence: 99%

Semaphorins and their receptors in lung cancer

2009

View full text Add to dashboard Cite

Semaphorins are a large family of secreted, transmembrane and GPI-linked proteins initially characterized in the development of the nervous system and axonal guidance. Semaphorins are expressed in many tissues where they regulate normal development, organ morphogenesis, immunity and angiogenesis. They affect the cytoskeleton, actin filament organization, microtubules and cell adhesion. Semaphorin signaling is transduced by plexins, which in the case of most class-3 semaphorins requires high affinity neuropilin receptors. The neuropilins also function as receptors for VEGF and other growth factors, and their expression is often abnormal in tumors. In cancer, semaphorins have both tumor suppressor and tumor promoting functions. We review here the current status of semaphorins and their receptors in tumor development with a focus on lung cancer.

show abstract

Section: Semaphorins In Lung Cancermentioning

confidence: 99%

Semaphorins and their receptors in lung cancer

2009

View full text Add to dashboard Cite

show abstract

“…In addition to its effect on tumor cells, SEMA3F also acts directly on vascular endothelial cells to inhibit steps in angiogenesis such as adhesion, migration, and capillary sprouting [31][32][33][34]. In the vascular system, NRP2 is expressed in both venous and lymphatic endothelial cells [35][36][37], which suggests that SEMA3F may be involved in lymphangiogenesis. However, there is very little evidence for a correlation between SEMA3F Grant sponsor: National Natural Science Foundation of China; Grant number: 305400083. expression and lymphangiogenesis, and although SEMA3F can effectively compete with VEGF for binding to NRP2 [38,39], little is known of how SEMA3F and VEGF-C may compete for receptor binding.…”

Section: Introductionmentioning

confidence: 99%